Whalesbook
📉 The Financial Deep Dive
Entero Healthcare Solutions Limited has posted robust Q3 FY26 financial results, showcasing significant year-over-year (YoY) growth across key metrics.
The Numbers:
Consolidated revenue surged by 25.6% YoY to ₹1,706.5 Cr in Q3 FY26, building on a 24.6% YoY growth for the nine-month period (9MFY26) to ₹4,681.3 Cr. Gross profit climbed 29.4% YoY to ₹172.6 Cr, with Gross Margins improving by 30 basis points (bps) YoY to 10.1%. EBITDA demonstrated substantial growth of 35.5% YoY to ₹67.8 Cr, leading to an expansion in EBITDA Margin by 29 bps YoY to 4.0%. For 9MFY26, EBITDA grew by a notable 46.7% YoY to ₹179.9 Cr, with EBITDA Margins expanding by 58 bps YoY to 3.8%.
Profit After Tax (PAT) to owners saw an 8.6% YoY increase to ₹27.6 Cr in Q3 FY26. However, PAT before exceptional items grew more robustly by 35.8% YoY to ₹40.0 Cr. This divergence was due to an exceptional item of ₹8.2 Cr related to the New Labour Code impact.
The Quality:
The company achieved a significant turnaround in operating cash flow, generating ₹49 Cr in Q3 FY26, a marked improvement from negative OCF in the preceding quarters of FY26. Net Working Capital (NWC) days stood at 64 days. Key profitability ratios improved, with ROCE increasing to 14.8% in Q3 FY26 from 13.8% in the prior quarter, and ROE (excluding one-off impact) at 12.3% compared to 11.0% QoQ.
The Grill:
An exceptional item of ₹8.2 Cr due to the New Labour Code impacted reported PAT. Excluding this, the PAT Margin for Q3 FY26 was 2.3%, highlighting underlying operational strength.
🚀 Strategic Analysis & Impact
Mr. Prabhat Agrawal, MD & CEO, emphasized a quarter of solid growth, underpinned by the highest organic like-for-like growth rate of 17.1% year-to-date. The company successfully closed four key acquisitions during Q3 FY26 and post-quarter: Anand Medilink Pvt. Ltd., Ace Cardiopathy Solutions Pvt. Ltd., Bioaide Technologies Pvt. Ltd., and Anand Chemiceutics. This aggressive M&A strategy is primarily targeting the high-growth MedTech segment, with projected MedTech revenue to exceed ₹1,000 Cr in FY27. The focus areas within MedTech are IVD, Cardiology, and Orthopedic devices.
The balance sheet reflects the acquisition spree, with Goodwill increasing from ₹192.8 Cr (March 2024) to ₹424.0 Cr (March 2025). Total borrowings saw a modest rise to ₹298.8 Cr as of March 2025, maintaining a low Debt-to-Equity ratio of approximately 0.17.
🚩 Risks & Outlook
While the growth trajectory is strong, Entero Healthcare faces inherent risks typical of rapid expansion and acquisitions. A recent development is a temporary three-day drug license suspension for its subsidiary, Atreja Healthcare Solutions, for violations of the Drugs and Cosmetics Act, resulting in a potential revenue loss of ₹1.88 million. Management stated this had no material impact on overall operations. Investors should monitor the successful integration of acquired entities, continued margin expansion, and sustained positive operating cash flow. The company is strategically positioned for accelerated growth and market consolidation.